Effective June 30, 2018, if you have not upgraded to a current browser you will no longer be able to view or make transactions on MerckVaccines.com. To protect your credit card information, Merck follows security requirements mandated by the PCI Security Standards Council. The PCI Security Standards Council has mandated that all companies that transact payments with credit cards must restrict the use of insecure browsers.
You can learn more about the specific PCI requirement here.
There is approximately a 2-fold risk for IPD in healthy adults aged ≥65 years compared to healthy adults aged 50–64 years.2,a
Certain chronic conditions increase the risk for IPD in adults (18–64 years).2,a
Chronic heart disease
Chronic lung disease
Risk versus healthy adultsa
aRetrospective cohort study using data from January 1, 2006, through December 31, 2010, from 3 health care claims databases representing >35 million insured adults ≥18 years of age. Risk for IPD was compared between healthy adults ≥65 years of age and healthy adults 50 to 64 years of age. Risk for IPD in adults with chronic conditions was compared to age-matched healthy counterparts.2
Diabetes mellitus may cause patients to be in a hyperglycemic state, which can functionally impair certain immune cells. This leads to reduced clearance of bacteria and increases the probability of infection.3
Chronic heart disease may cause inadequate cardiac output that causes lung congestion. This in turn leads to reduced clearance of bacteria and may increase the risk for infection.4,5,6
Chronic lung disease (COPD) causes chronic lung inflammation and impaired functionality of certain cells of the immune system, which reduces clearance of bacteria and potentially leads to infection.7
There are many reasons why older patients are more susceptible to pneumococcal disease. For example, the cough mechanism becomes less effective, and the immune system weakens, increasing the susceptibility to pneumococcal disease.2,8,9
Although noninvasive pneumococcal pneumonia is more prevalent than invasive disease, the diagnosis is often difficult to make, and confirming, for example, that a case of pneumonia is definitively caused by Streptococcus pneumoniae can be challenging.10
For this reason, invasive pneumococcal disease is a reliable indicator of overall pneumococcal disease burden.10
DISCLAIMER: By clicking on the link below, you will be directed away from MerckVaccines.com to another Web site. Merck does not review or control the content of the site to which the hyperlink connects; therefore, the hyperlink does not constitute an endorsement by Merck.
CDC=Centers for Disease Control and Prevention; COPD=chronic obstructive pulmonary disease.
Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1–24.
Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):1–9.
Boyanova L, Mitov I. Antibiotic resistance rates in causative agents of infections in diabetic patients: rising concerns. Expert Rev Anti Infect Ther.2013;11(4):411–420.
Lung congestion. Encyclopædia Britannica. http://www.britannica.com/EBchecked/topic/351528 /lung-congestion. Accessed August 31, 2017.
Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med. 2005;353(26):2788–2796.
Mor A, Thomsen RW, Ulrichsen SP, et al. Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. Eur J Intern Med.2013;24(4):349–353.
Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71–86.
Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 2. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:2623–2642.
Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int.2009;22(11):1041–1050.
World Health Organization (WHO). 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec.2008;83(42):373–384. http://www.who.int/wer/2008/wer8342.pdf. Accessed August 31, 2017.